LoginRegister
    Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancerMerck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer
    Genentech,BARDA gets USFDA nod for Actemra Clinical Trial in COVID-19 patientsGenentech,BARDA gets USFDA nod for Actemra Clinical Trial in COVID-19 patients
    100 distilleries and more than 500 manufacturers permitted to produce hand sanitizers by Government100 distilleries and more than 500 manufacturers permitted to produce hand sanitizers by Government
    Caplin Steriles gets USFDA approval for Verapamil Hydrochloride InjectionCaplin Steriles gets USFDA approval for Verapamil Hydrochloride Injection
    Hydroxychloroquine now a Prescription Drug: Health Ministry gazette puts it in Schedule H1 of DCAHydroxychloroquine now a Prescription Drug: Health Ministry gazette puts it in Schedule H1 of DCA
    Cipla gets USFDA final nod for Esomeprazole ANDA for Oral SuspensionCipla gets USFDA final nod for Esomeprazole ANDA for Oral Suspension
    Strides Pharma gets USFDA EIR for its Bangalore flagship facilityStrides Pharma gets USFDA EIR for its Bangalore flagship facility
    Lupin appoints Ramesh Swaminathan as CFO, Head Corporate AffairsLupin appoints Ramesh Swaminathan as CFO, Head Corporate Affairs
    Mylab ships first batch of COVID-19 test kits to government and private labsMylab ships first batch of COVID-19 test kits to government and private labs
    Shortage of API: Bengal Chemicals can only supply only 10 lakh hydroxy-chloroquineShortage of API: Bengal Chemicals can only supply only 10 lakh hydroxy-chloroquine
    Beware of fake COVID-19 cyber cures warns EU medicines agencyBeware of fake COVID-19 cyber cures warns EU medicines agency
    BAN on export of anti-malarial drug hydroxycloroquine with immediate effect: GovtBAN on export of anti-malarial drug hydroxycloroquine with immediate effect: Govt
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X